Leerink Partners upgraded Bristol-Myers Squibb (NYSE:BMY) to Outperform from Market Perform on Tuesday, boosting sales ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Fintel reports that on November 13, 2024, Leerink Partners downgraded their outlook for 908 Devices (NasdaqGM:MASS) from ...

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...

In a report released yesterday, Daina Graybosch from Leerink Partners maintained a Hold rating on Turnstone Biologics Corp. (TSBX – ...

Investment analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of Xencor in a ...

Stock analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for shares of Zymeworks in a ...

Beam Therapeutics (BEAM) stock gains as Leerink upgrades the biotech despite a fatality in a gene editing study, citing an ...

Dentsply Sirona (XRAY) stock fell as the company with its Q3 2024 lowered full-year outlook, prompting a downgrade from Leerink Partners. Read more here.

On Thursday, Leerink Partners adjusted their stance on Dentsply Sirona (NASDAQ: XRAY), shifting the rating to Market Perform from Outperform. The decision came as a response to the company's third ...

Fintel reports that on November 7, 2024, Leerink Partners downgraded their outlook for DENTSPLY SIRONA (WBAG:XRAY) from Outperform to Market Perform. There are 910 funds or institutions reporting ...

Fintel reports that on November 7, 2024, Leerink Partners upgraded their outlook for Zymeworks (NasdaqGS:ZYME) from Market Perform to Outperform. As of October 22, 2024, the average one-year price ...